Although several therapeutic agents have been evaluated for the treatment of corona virus disease 2019 (Covid-19) none have yet been shown to be efficacious in taming the global pandemic.
A double-blind, randomized, placebo-controlled trial of intravenous Remdesivir in adults hospitalized with Covid-19 in the above named isolation centre was conducted with evidence of lower respiratory tract involvement.
Patients were randomly assigned to receive either Remdesivir (200mg) loading dose on Day one (1), followed by 100mg daily for upto (nine) additional days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only.
A total of 1064 patients underwent randomization. The data and safety monitoring board recommended early unbinding of the results on the basis of findings from an analysis that showed shortened time to recovery in the remdesivir group.
Preliminary results from the 1059 patients (538 assigned to remdesivir in and 521 to placebo) with data available after randomization indicated that those who received Remdesivir had Remdesivir had a median recovery time of 11 days (95% confidence interval (Cl), 9 to 12), as compared with 15 days (95%Cl 13 to 19) in those who received placebo (rate ratio for recovery 1.32, 95% Cl, 1.12 to 1.55; P<0.001). The Kaplan-Meier estimates of mortality by 14 days were 7.1% with Remdesivir and 11.9% serious adverse events were reposted for 114 of the 541 patients in the Remdesivir group that underwent randomization (21.1%) and 141 of the 522 patients in the placebo group that undergoes randomization (27.0%).
Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with covid-19 and evidence of lower respiratory tract infection.
0 Comments